Unknown

Dataset Information

0

A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells.


ABSTRACT: Although chemokine and growth factor receptors are attractive and popular targets for cancer therapeutic intervention, structure-based targeting of the ligands themselves is generally not considered practical. New evidence indicates that a notable exception to this is macrophage migration inhibitory factor (MIF). MIF, an autocrine- and paracrine-acting cytokine/growth factor, plays a pivotal role in both the initiation and maintenance of neoplastic diseases. MIF possesses a nonphysiologic enzymatic activity that is evolutionarily well-conserved. Although small molecule antagonists of MIFs enzymatic active site have been reported to inhibit biological activities of MIF, universally high IC(50)s have limited their clinical appeal. Using a computational virtual screening strategy, we have identified a unique small molecule inhibitor that serves as a suicide substrate for MIF, resulting in the covalent modification of the catalytically active NH(2)-terminal proline. Our studies further reveal that this compound, 4-iodo-6-phenylpyrimidine (4-IPP), is approximately 5x to 10x times more potent in blocking MIF-dependent catalysis and lung adenocarcinoma cell migration and anchorage-independent growth than the prototypical MIF inhibitor, ISO-1. Finally, using an in silico combinatorial optimization strategy, we have identified four unique congeners of 4-IPP that exhibit MIF inhibitory activity at concentrations 10x to 20x lower than that of parental 4-IPP.

SUBMITTER: Winner M 

PROVIDER: S-EPMC2726006 | biostudies-literature | 2008 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

A novel, macrophage migration inhibitory factor suicide substrate inhibits motility and growth of lung cancer cells.

Winner Millicent M   Meier Jason J   Zierow Swen S   Rendon Beatriz E BE   Crichlow Gregg V GV   Riggs Randall R   Bucala Richard R   Leng Lin L   Smith Ned N   Lolis Elias E   Trent John O JO   Mitchell Robert A RA  

Cancer research 20080901 18


Although chemokine and growth factor receptors are attractive and popular targets for cancer therapeutic intervention, structure-based targeting of the ligands themselves is generally not considered practical. New evidence indicates that a notable exception to this is macrophage migration inhibitory factor (MIF). MIF, an autocrine- and paracrine-acting cytokine/growth factor, plays a pivotal role in both the initiation and maintenance of neoplastic diseases. MIF possesses a nonphysiologic enzyma  ...[more]

Similar Datasets

| S-EPMC2970845 | biostudies-literature
| S-EPMC4398672 | biostudies-literature
| S-EPMC4497763 | biostudies-literature
| S-EPMC4491511 | biostudies-other
2022-04-08 | PXD031143 | Pride
| S-EPMC3926510 | biostudies-literature
| S-EPMC1989118 | biostudies-literature
| S-EPMC4415022 | biostudies-literature
| S-EPMC2786800 | biostudies-literature
| S-EPMC8553141 | biostudies-literature